{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:29:03Z","timestamp":1785295743473,"version":"3.55.0"},"reference-count":82,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,2,6]],"date-time":"2013-02-06T00:00:00Z","timestamp":1360108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sodium glucose co\u2010transporter\u20102 (\n                    <jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content>\n                    ) inhibitors are an emerging class of glucose\u2010lowering drugs in the management of type 2 diabetes mellitus (\n                    <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                    ). In this context,\n                    <jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content>\n                    is a low\u2010affinity, high\u2010capacity transporter that is expressed predominantly in the proximal renal tubules. The rationale for using\n                    <jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content>\n                    inhibition as a drug for\n                    <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                    is derived from early evidence obtained from individuals with familial renal glycosuria, due to a\n                    <jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content>\n                    mutation, which exhibits decreased renal tubular reabsorption of glucose in the absence of hyperglycaemia or any other signs of dysfunction. Thus, reduction of glucose reabsorption by\n                    <jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content>\n                    inhibition represents a novel\n                    <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                    treatment approach. In light of the emerging role of\n                    <jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content>\n                    inhibition in controlling glucose homeostasis, the current review provides a critical appraisal of the rationale, overviews of structural differences between\n                    <jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content>\n                    inhibitors and summarizes recent preclinical and clinical studies. The physiological actions of\n                    <jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content>\n                    inhibition in relation to insulin sensitivity, islet morphology, inflammation, body weight and blood pressure are reviewed. Finally, the safety and tolerability of\n                    <jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content>\n                    inhibitors are also discussed in relation to their potential to provide insulin independence and enhance \u03b2\u2010cell function, as well as their potential for synergistic\/additive effects if used in combination with other antidiabetic drugs.\n                  <\/jats:p>","DOI":"10.1111\/dom.12064","type":"journal-article","created":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T13:50:55Z","timestamp":1358430655000},"page":"392-402","source":"Crossref","is-referenced-by-count":52,"title":["Inhibition of the sodium glucose co\u2010transporter\u20102: its beneficial action and potential combination therapy for type 2 diabetes mellitus"],"prefix":"10.1111","volume":"15","author":[{"given":"L. H.","family":"Chen","sequence":"first","affiliation":[{"name":"School of Biomedical Sciences, Faculty of Medicine The Chinese University of Hong Kong  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S.","family":"Leung","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, Faculty of Medicine The Chinese University of Hong Kong  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,6]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10761"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01187.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)83060-X"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2009.48"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112981"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116972"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.2001.280.1.F10"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.06.033"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.016"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.12.027"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.17.10073"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(02)00416-X"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00422.2007"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000092790.89332.D2"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh366"},{"key":"e_1_2_5_17_1","first-page":"156","article-title":"Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0)","volume":"27","author":"Oemar B","year":"1987","journal-title":"Clin Nephrol"},{"key":"e_1_2_5_18_1","first-page":"289","article-title":"Immunological characterization of renal glycosuria patients","volume":"56","author":"Paoli PD","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00232-001-0036-y"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1088"},{"key":"e_1_2_5_21_1","unstructured":"Skyler JS. Insulin therapy in type 2 diabetes mellitus. In: DeFronzo RA ed. Current Therapy of Diabetes Mellitus. St Louis MO: Mosby\u2010Year Book 1998."},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.532"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.9.1794"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvp190"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.110296"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.140210"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.07.082"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm701272q"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100332n"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-011-0713-z"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.191593"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901893x"},{"issue":"1","key":"e_1_2_5_33_1","first-page":"S348","article-title":"Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin","volume":"53","author":"Wilding J","year":"2010","journal-title":"Diabetologia"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.251"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.250"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0612"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-010-0007-3"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01462.x"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009351879"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009352185"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01558.x"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0517"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.689956"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1926"},{"key":"e_1_2_5_47_1","unstructured":"ListJF WooVC VillegasEM TangW FiedorekFT. Dapagliflozin\u2010induced glucosuria is accompanied by weight loss in type 2 diabetes patients. Program and abstracts of the 68th Scientific Sessions of the American Diabetes Association San Francisco California June 6\u201310 2008 (Abstract 461\u2010P)."},{"key":"e_1_2_5_48_1","unstructured":"Administration TFaD. FDA Briefing Document NDA 202293. Dapagliflozin tablets 5 and 10 mg. Silver Spring MD 20993\u2013002 2011: P14\u201020"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60216-5"},{"key":"e_1_2_5_50_1","unstructured":"Administration TFaD. FDA Briefing Document NDA 202293. Dapagliflozin tablets 5 and 10mg.Silver Spring MD 20993\u20130022011:Statistical briefing material"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/414788a"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020735"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05485"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25102"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1472"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01291.x"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.2174\/156652412802480970"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01340.x"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.07.001"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200215318"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.140210"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1328"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730120-00005"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030555"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01558.x"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1863"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01216.x"},{"key":"e_1_2_5_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.59"},{"key":"e_1_2_5_70_1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"Group UPDS","year":"1998","journal-title":"BMJ"},{"key":"e_1_2_5_71_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.17925\/USE.2009.05.1.75","article-title":"The importance of reducing hyperglycemia while preserving insulin secretion\u2014the rationale for sodium\u2010coupled glucose co\u2010transporter 2 inhibition in diabetes","volume":"5","author":"Jabbour SA","year":"2009","journal-title":"US Endocrinology"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0098-x"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164112441190"},{"key":"e_1_2_5_74_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2337\/diab.34.8.793","article-title":"U.K. Prospective Diabetes Study: II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity\u2010onset diabetes","volume":"34","author":"Study AM","year":"1985","journal-title":"Diabetes"},{"key":"e_1_2_5_75_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030861"},{"key":"e_1_2_5_76_1","doi-asserted-by":"crossref","unstructured":"Williams\u2010Herman D Johnson J Teng R et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.Diabetes Obes Metab;12: 442\u2013451.","DOI":"10.1111\/j.1463-1326.2010.01204.x"},{"key":"e_1_2_5_77_1","unstructured":"Kawamori R Inagaki N Araki E et al. Linagliptin monotherapy improves glycemic control in Japanese patients with T2DM over 12 weeks. 70th ADA Scientific Sessions Orlando Florida USA 2010: 696\u2010P."},{"key":"e_1_2_5_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01385.x"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12047"},{"key":"e_1_2_5_80_1","unstructured":"Ferrannini E. BI\u201010773 improves glycemic control in large study in type 2 diabetes.Diabetologia2010;53(Suppl. 1): Abst 877."},{"key":"e_1_2_5_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.58"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.01.001"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101072y"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12064","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:00:26Z","timestamp":1761879626000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,6]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1111\/dom.12064"],"URL":"https:\/\/doi.org\/10.1111\/dom.12064","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,6]]}}}